130 related articles for article (PubMed ID: 7919457)
1. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines.
Hill BT; Shellard SA; Fichtinger-Schepman AM; Schmoll HJ; Harstrick A
Anticancer Drugs; 1994 Jun; 5(3):321-8. PubMed ID: 7919457
[TBL] [Abstract][Full Text] [Related]
2. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
Shellard SA; Hosking LK; Hill BT
Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
[TBL] [Abstract][Full Text] [Related]
4. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA
Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544
[TBL] [Abstract][Full Text] [Related]
5. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
Shellard SA; Fichtinger-Schepman AM; Lazo JS; Hill BT
Anticancer Drugs; 1993 Aug; 4(4):491-500. PubMed ID: 8400352
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
7. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
9. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
10. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
11. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.
Bedford P; Fichtinger-Schepman AM; Shellard SA; Walker MC; Masters JR; Hill BT
Cancer Res; 1988 Jun; 48(11):3019-24. PubMed ID: 3365691
[TBL] [Abstract][Full Text] [Related]
12. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
[TBL] [Abstract][Full Text] [Related]
13. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
Maynard KR; Hosking LK; Hill BT
Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540
[TBL] [Abstract][Full Text] [Related]
14. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
15. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.
Blommaert FA; Floot BG; van Dijk-Knijnenburg HC; Berends F; Baan RA; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Chem Biol Interact; 1998 Jan; 108(3):209-25. PubMed ID: 9528691
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin.
Trimmer EE; Essigmann JM
Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
[TBL] [Abstract][Full Text] [Related]
17. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
18. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
Zhen W; Link CJ; O'Connor PM; Reed E; Parker R; Howell SB; Bohr VA
Mol Cell Biol; 1992 Sep; 12(9):3689-98. PubMed ID: 1380646
[TBL] [Abstract][Full Text] [Related]
19. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
20. DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR
Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
